ESMO Asia 2023 | New biomarker imaging techniques to improve MK-2206 efficacy in breast cancer

Jiang Zhang, PhD, The Hong Kong Polytechnic University, Hong Kong, China, explains how dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is useful in studying the mechanisms of MK-2206 in early-stage, high-risk breast cancer. The Akt inhibitor was used in the I-SPY2 trial (NCT01042379) that tested new drugs in patients with high-risk breast cancer. MK-2206 produced promising pathological complete responses in patients, although its efficacy was limited; Dr Zhang’s team are utilizing non-invasive biomarker imaging to better select drug responses and are particularly interested in the correlation between biomarker value and tumour immune microenvironment, ultimately hoping to improve responses for patients. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.